Literature DB >> 10965096

Antibiotic susceptibility of Serratia marcescens and Serratia liquefaciens.

W H Traub1.   

Abstract

BACKGROUND: Over a period of 20 years, a total of 1,603 Serratia isolates were recovered from clinical specimens and examined for susceptibility to 29 antimicrobial drugs using the Bauer-Kirby agar disk diffusion test. Serratia marcescens was recovered most frequently (n = 1,409), followed by S. liquefaciens (n = 172); other Serratia species were scarce. During the 2-decade observation period there occurred 35 putative episodes/clusters of nosocomial cross-infection and 1 pseudo-outbreak due to S. marcescens, but none due to S. liquefaciens.
METHODS: The antimicrobial susceptibility data for S. marcescens and S. liquefaciens were subdivided into two observation periods: I = 1980-1993, and II = 1993-1999. The crude data (series A) obtained for S. marcescens were corrected in two ways: by the omission of repetitive patient isolates (series B) and the additional removal of outbreak isolates except for index case isolates (series C). RESULTS AND
CONCLUSIONS: Comparison of data obtained in series IC and IIC disclosed an increase in the susceptibility of S. marcescens to ampicillin + sulbactam, cefotaxime, chloramphenicol, doxycycline, fosfomycin, gentamicin, piperacillin, piperacillin + tazobactam, timentin and tobramycin during observation period II. Conversely, there was a decrease in susceptibility to ciprofloxacin, nalidixic acid and trovafloxacin, and slightly diminished susceptibility to norfloxacin and ofloxacin during observation period II as compared with the previous period. The crude data obtained for S. liquefaciens required no correction, as there were only a few repeat isolates. There was an increase in susceptibility to ampicillin, ampicillin + sulbactam, cefuroxime, doxycycline, fosfomycin, nitrofurantoin and polymyxin B (clear inhibition zones). However, there was an inexplicable decrease in susceptibility to piperacillin + tazobactam. Cocarde growth around polymyxin B disks was noted with 55.8% of the S. marcescens isolates as compared with 6.8% of the S. liquefaciens isolates. Slime around fluoroquinolone inhibition zones was produced by 83.4% of the S. marcescens isolates. Slime production around carbapenem inhibition zones was noted with 52% of the S. liquefaciens isolates, but with only a single isolate of S. marcescens. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10965096     DOI: 10.1159/000007304

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  7 in total

1.  Biofilm Formation and Quorum-Sensing-Molecule Production by Clinical Isolates of Serratia liquefaciens.

Authors:  Sara Remuzgo-Martínez; María Lázaro-Díez; Celia Mayer; Maitane Aranzamendi-Zaldumbide; Daniel Padilla; Jorge Calvo; Francesc Marco; Luis Martínez-Martínez; José Manuel Icardo; Ana Otero; José Ramos-Vivas
Journal:  Appl Environ Microbiol       Date:  2015-03-06       Impact factor: 4.792

2.  Role of a Small Molecule in the Modulation of Cell Death Signal Transduction Pathways.

Authors:  Stella Hartmann; David J Nusbaum; Kevin Kim; Saleem Alameh; Chi-Lee C Ho; Renae L Cruz; Anastasia Levitin; Kenneth A Bradley; Mikhail Martchenko
Journal:  ACS Infect Dis       Date:  2018-11-05       Impact factor: 5.084

3.  Inhibition of Quorum Sensing Mediated Virulence Factors Production in Urinary Pathogen Serratia marcescens PS1 by Marine Sponges.

Authors:  Angusamy Annapoorani; Abdul Karim Kamil Abdul Jabbar; Syed Khadar Syed Musthafa; Shunmugiah Karutha Pandian; Arumugam Veera Ravi
Journal:  Indian J Microbiol       Date:  2012-05-23       Impact factor: 2.461

4.  Mixed Mycobacterium Avium-Intracellulare and Serratia Marcescens Cellulitis of the Breast in an HIV-Negative Patient with Breast Cancer: A Case Report.

Authors:  Andreas Kyvernitakis; Jacques Azzi; Dimitrios P Kontoyiannis
Journal:  Cureus       Date:  2016-06-09

5.  Silencing the nosocomial pathogen Serratia marcescens by glyceryl trinitrate.

Authors:  Hisham A Abbas; Ahmed M Elsherbini
Journal:  Afr Health Sci       Date:  2018-03       Impact factor: 0.927

6.  Repurposing of antidiabetics as Serratia marcescens virulence inhibitors.

Authors:  Wael A H Hegazy; Maan T Khayat; Tarek S Ibrahim; Mahmoud Youns; Rasha Mosbah; Wafaa E Soliman
Journal:  Braz J Microbiol       Date:  2021-03-08       Impact factor: 2.476

7.  Repurposing anti-diabetic drug "Sitagliptin" as a novel virulence attenuating agent in Serratia marcescens.

Authors:  Hisham A Abbas; Wael A H Hegazy
Journal:  PLoS One       Date:  2020-04-16       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.